Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Statin Use in Patients With Acute VTE
NCT02331095 · Ohio State University · EARLY_PHASE1 · terminated · last registry update 2020-10-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment” | – | Registry record, Ohio State University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HMGCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-27Phase 3 first posted: The George Institute, Atorvastatin (NCT04904536)
- 2021-05-12Phase 3 first posted: Universitaire Ziekenhuizen KU Leuven, Rosuvastatin 10mg (NCT04883840)
- 2020-12-16Phase 3 first posted: Sanofi, Rosuvastatin + SPC ezetimibe/rosuvastatin (NCT04669041)
- 2020-10-26Phase 3 first posted: EMS, BERLIM 25/20 ASSOCIATION + EMPAGLIFLOZIN (NCT04602754)
- 2020-03-24Phase 3 first posted: Ottawa Hospital Research Institute, Rosuvastatin Calcium + Placebo Oral Tablet (NCT04319627)
- 2019-10-21Phase 3 first posted: Annika Bergquist, Simvastatin 40mg + Placebo oral tablet (NCT04133792)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision